Practical guide finds growing evidence for cannabinoids in autism, Tourette syndrome, anxiety, and PTSD
A clinical review finds increasing evidence for cannabinoids in ASD, Tourette syndrome, anxiety, and PTSD, with practical dosing: start 1-2.5 mg THC/day, titrate to 10-20 mg daily.
Quick Facts
What This Study Found
Increasing evidence supports cannabinoids for ASD, Tourette syndrome, anxiety disorders, and PTSD. THC-containing extracts may serve as substitution therapy for CUD. Practical dosing: start 1-2.5 mg THC/day, titrate by 1-2.5 mg every 3-5 days, target 10-20 mg/day. CBD requires >400 mg/day.
Key Numbers
Starting dose: 1-2.5 mg THC/day. Titration: 1-2.5 mg every 3-5 days. Target: 10-20 mg THC/day. CBD: >400 mg/day. No approved psychiatric indications.
How They Did This
Clinical review and practical overview of cannabinoids for mental illnesses, including treatment protocols and dosing guidance.
Why This Research Matters
As more patients self-medicate with cannabis, clinicians need practical guidance on when cannabinoids may be appropriate and how to dose them.
The Bigger Picture
The gap between patient self-medication and clinical evidence is narrowing, with evidence accumulating enough to inform clinical decision-making for specific conditions.
What This Study Doesn't Tell Us
Narrative review. Most evidence is preliminary. Dosing based on clinical experience as much as controlled data.
Questions This Raises
- ?Will any cannabinoid achieve psychiatric regulatory approval soon?
- ?Can the endocannabinoid system's stress management role be leveraged therapeutically?
Trust & Context
- Key Stat:
- average daily THC dose for psychiatric symptom management, starting from 1-2.5 mg with slow titration
- Evidence Grade:
- Practical clinical review with expert dosing recommendations. Evidence quality varies significantly by condition.
- Study Age:
- 2024 publication.
- Original Title:
- Cannabinoids in the Treatment of Selected Mental Illnesses: Practical Approach and Overview of the Literature.
- Published In:
- Pharmacopsychiatry, 57(3), 104-114 (2024)
- Authors:
- Müller-Vahl, Kirsten R(12)
- Database ID:
- RTHC-05575
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Can cannabis treat mental illness?
No cannabis product is approved for any mental illness. Growing evidence supports potential benefits in Tourette syndrome, PTSD, anxiety, and autism. Clinical use remains off-label.
What is the right dose?
Start at 1-2.5 mg THC/day, increase by 1-2.5 mg every 3-5 days to 10-20 mg/day. CBD requires much higher doses, above 400 mg/day.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-05575APA
Müller-Vahl, Kirsten R. (2024). Cannabinoids in the Treatment of Selected Mental Illnesses: Practical Approach and Overview of the Literature.. Pharmacopsychiatry, 57(3), 104-114. https://doi.org/10.1055/a-2256-0098
MLA
Müller-Vahl, Kirsten R. "Cannabinoids in the Treatment of Selected Mental Illnesses: Practical Approach and Overview of the Literature.." Pharmacopsychiatry, 2024. https://doi.org/10.1055/a-2256-0098
RethinkTHC
RethinkTHC Research Database. "Cannabinoids in the Treatment of Selected Mental Illnesses: ..." RTHC-05575. Retrieved from https://rethinkthc.com/research/muller-vahl-2024-cannabinoids-in-the-treatment
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.